Skip to main content

Day: May 16, 2025

Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. “The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline,” said Jed Latkin, Chief Executive Officer of Windtree. Mr. Latkin continued, “We believe that this strategy has the potential to transform Windtree into both a commercial and development...

Continue reading

OptimizeRx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025 Stifel 2025 Boston Cross Sector 1×1 Conference, Boston, June 3 – 4, 2025 45th Annual William Blair Growth Stock Conference, Chicago, June 3 – 5, 2025 The Citizens Medical Devices and Healthcare Services Forum, Boston, June 17, 2025B. Riley Securities 25th Annual Investor ConferenceDate:  Thursday, May 22, 2025Format: 1×1 Meetings & Fireside ChatLocation: The Ritz-Carlton, Marina...

Continue reading

AgEagle Aerial Systems Reports First Quarter Fiscal Year 2025 Financial Results

Improved financial performance highlighted by strong gross margin improvement and significant reduction in operating expenses  WICHITA, Kan., May 16, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of best-in-class unmanned aerial systems (UAS) and sensors for military, public safety, and commercial use, announces its financial results for the first quarter ended March 31, 2025, highlighted by gross margin improvement and significant reduction in operating expenses. Financial Highlights for the Quarter Ended March 31, 2025Net income was $7.06 million, compared to a net loss of $6.32 million in Q1 2024, reflecting an income increase of 211.8%. The increase in net income was primarily attributable to the gain on change in fair value of our outstanding warrant liabilities and reductions of costs...

Continue reading

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025. Quantum BioPharma Head of Finance and M&A Jason Sawyer will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22, where Mr. Sawyer is scheduled to host one-on-one meetings with institutional investors at both events and host a webcast presentation at the Sidoti Micro-Cap Conference. Sidoti Micro-Cap Conference Date: Wednesday, May 21, 2025Format: Presentation & Virtual 1×1 MeetingsPresentation:...

Continue reading

Brady Corporation Reports Record Adjusted EPS in its Fiscal 2025 Third Quarter and Tightens its Fiscal 2025 EPS Guidance

Sales for the quarter increased 11.4 percent. Organic sales increased 1.6 percent, acquisitions increased sales 10.5 percent and foreign currency translation decreased sales 0.7 percent. Diluted EPS increased 3.8 percent to $1.09 in the third quarter of fiscal 2025 compared to $1.05 in the same quarter of the prior year. Adjusted Diluted EPS* increased 11.9 percent to a record high of $1.22 in the third quarter of fiscal 2025 compared to $1.09 in the same quarter of the prior year. Returned $44.5 million in the quarter to shareholders in the form of dividends and share repurchases. The Company’s Adjusted Diluted EPS* Guidance range for the full year ending July 31, 2025 was tightened from a range of $4.45 to $4.70 per share to $4.48 to $4.63 per share, and the previous range of GAAP earnings per diluted Class A Nonvoting Common share...

Continue reading

Form 8.3 – [GLOBALDATA PLC – 15 05 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree GLOBALDATA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition to new leadership. A search for Lars Fruergaard Jørgensen’s successor is ongoing, and an announcement will be made in due course. In connection with the change, Lars Rebien Sørensen, chair of the Novo Nordisk Foundation, will join the Novo Nordisk Board, initially as an observer. Novo Nordisk has been through a significant growth journey and transformation led by Lars Fruergaard Jørgensen. During his eight-year tenure as CEO, Novo Nordisk’s sales, profits and share price have almost tripled. Novo Nordisk has a clear strategy,...

Continue reading

reAlpha Tech Corp. Announces 4,432% Year-over-Year Revenue Growth for Quarter Ended March 31, 2025

DUBLIN, Ohio, May 16, 2025 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), a real estate technology company developing and commercializing artificial intelligence (“AI”) technologies, today announced financial results for the quarter ended March 31, 2025. Financial Highlights:Revenue increased 4,432% to $925,635 in the first quarter of 2025, compared to $20,426 in the first quarter of 2024. Cash was approximately $1.2 million as of the first quarter of 2025, compared to $3.1 million in the first quarter of 2024. Net loss was approximately $2.85 million in the first quarter of 2025, compared to a net loss of approximately $1.41 million in the first quarter of 2024, which increase in net loss was mainly due to increased operating expenses resulting from the integration of the Company’s recent...

Continue reading

Gaming and Leisure Properties, Inc. Declares Increased Second Quarter 2025 Cash Dividend of $0.78 Per Share

WYOMISSING, Pa., May 16, 2025 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”), announced today that at its meeting yesterday the Company’s Board of Directors declared the second quarter 2025 cash dividend of $0.78 per share of its common stock, marking an increase of $.02 per share per quarter from the prior level. The dividend is payable on June 27, 2025 to shareholders of record on June 13, 2025. The second quarter 2024 cash dividend was $0.76 per share of the Company’s common stock. Based on yesterday’s closing price of $46.89 per share of common stock, on an annualized basis, the new dividend payout reflects a yield of 6.65%. While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends will be reviewed quarterly and declared by the...

Continue reading

ECARX Debuts EXP01 Processor at RISC-V Summit Europe 2025, Outlines Next-Generation MCU Roadmap and Global RISC-V Strategy

SHANGHAI, May 16, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, announced the debut of its EXP01 processor built on the RISC-V architecture at the RISC-V Summit Europe 2025 which was held from May 12-15, 2025, in Paris. Alongside this technical breakthrough, ECARX also outlined its roadmap for the next-generation MCU, deepened technical collaborations with the RISC-V ecosystem, and reaffirmed its commitment to accelerating RISC-V adoption in intelligent mobility solutions. RISC-V is a completely open-source instruction-set architecture that provides a simple, modular foundation for building customized processors. Unlike proprietary chip designs, RISC-V lets engineers identify and select only the features they need, enabling faster innovation, lower power consumption,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.